News headlines about Chiasma (NASDAQ:CHMA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chiasma earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.4715670353041 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Separately, ValuEngine upgraded shares of Chiasma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Chiasma (NASDAQ CHMA) traded down $0.05 during mid-day trading on Thursday, hitting $1.90. 16,200 shares of the stock traded hands, compared to its average volume of 86,296. Chiasma has a fifty-two week low of $1.25 and a fifty-two week high of $2.95.

In other news, Director Scott Minick bought 25,000 shares of the firm’s stock in a transaction dated Thursday, September 21st. The stock was acquired at an average cost of $2.37 per share, for a total transaction of $59,250.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/chiasma-chma-receiving-somewhat-favorable-media-coverage-study-finds/1735390.html.

About Chiasma

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.